Cargando…

Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor

Background: Botulinum toxin type A (BoNT-A) therapy for upper-limb tremor has emerged as a promising option. However, it is unclear in real-world practices whether a technology-guided approach can compare with expert clinical assessments (including surface anatomy and palpation) for improving outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Samotus, Olivia, Mahdi, Yekta, Jog, Mandar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413198/
https://www.ncbi.nlm.nih.gov/pubmed/36006219
http://dx.doi.org/10.3390/toxins14080557
_version_ 1784775683262644224
author Samotus, Olivia
Mahdi, Yekta
Jog, Mandar
author_facet Samotus, Olivia
Mahdi, Yekta
Jog, Mandar
author_sort Samotus, Olivia
collection PubMed
description Background: Botulinum toxin type A (BoNT-A) therapy for upper-limb tremor has emerged as a promising option. However, it is unclear in real-world practices whether a technology-guided approach can compare with expert clinical assessments (including surface anatomy and palpation) for improving outcomes. This retrospective study aims to review our clinical outcomes of treating essential tremor (ET) and Parkinson’s disease (PD) tremor using either clinical- or kinematic-based injection pattern determination methods. Methods: 68 ET and 45 PD patients received at least one injection for their upper-limb tremor (unilateral or bilateral) in the last 7 years. Demographics of patients and BoNT-A injections were collected. A Mann–Whitney U statistical test was used to compare outcome measures between ET and PD cohorts. Results: Mean age (72 ± 9 years), number of injections (5), years receiving therapy (~2 years), clinic- (~57%) or kinematic-based patterns, and self-paying (52%) were similar between both cohorts. BoNT-A as a monotherapy in both upper limbs was received in more ET than PD patients. Double reconstitution of Xeomin(®) in the wrist flexors/extensors, supinator, biceps, and triceps were most injected. Discontinuation due to no benefit/weakness was not dependent on the injection pattern determination approach. Conclusions: Kinematic-based BoNT-A injections produced similar treatment outcomes to injections based on the clinical expertise of the expert injector. This suggests that kinematics could be used by a non-expert to attain equivalent efficacy potentially improving access to this treatment.
format Online
Article
Text
id pubmed-9413198
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94131982022-08-27 Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor Samotus, Olivia Mahdi, Yekta Jog, Mandar Toxins (Basel) Article Background: Botulinum toxin type A (BoNT-A) therapy for upper-limb tremor has emerged as a promising option. However, it is unclear in real-world practices whether a technology-guided approach can compare with expert clinical assessments (including surface anatomy and palpation) for improving outcomes. This retrospective study aims to review our clinical outcomes of treating essential tremor (ET) and Parkinson’s disease (PD) tremor using either clinical- or kinematic-based injection pattern determination methods. Methods: 68 ET and 45 PD patients received at least one injection for their upper-limb tremor (unilateral or bilateral) in the last 7 years. Demographics of patients and BoNT-A injections were collected. A Mann–Whitney U statistical test was used to compare outcome measures between ET and PD cohorts. Results: Mean age (72 ± 9 years), number of injections (5), years receiving therapy (~2 years), clinic- (~57%) or kinematic-based patterns, and self-paying (52%) were similar between both cohorts. BoNT-A as a monotherapy in both upper limbs was received in more ET than PD patients. Double reconstitution of Xeomin(®) in the wrist flexors/extensors, supinator, biceps, and triceps were most injected. Discontinuation due to no benefit/weakness was not dependent on the injection pattern determination approach. Conclusions: Kinematic-based BoNT-A injections produced similar treatment outcomes to injections based on the clinical expertise of the expert injector. This suggests that kinematics could be used by a non-expert to attain equivalent efficacy potentially improving access to this treatment. MDPI 2022-08-17 /pmc/articles/PMC9413198/ /pubmed/36006219 http://dx.doi.org/10.3390/toxins14080557 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Samotus, Olivia
Mahdi, Yekta
Jog, Mandar
Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title_full Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title_fullStr Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title_full_unstemmed Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title_short Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
title_sort real-world longitudinal experience of botulinum toxin therapy for parkinson and essential tremor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413198/
https://www.ncbi.nlm.nih.gov/pubmed/36006219
http://dx.doi.org/10.3390/toxins14080557
work_keys_str_mv AT samotusolivia realworldlongitudinalexperienceofbotulinumtoxintherapyforparkinsonandessentialtremor
AT mahdiyekta realworldlongitudinalexperienceofbotulinumtoxintherapyforparkinsonandessentialtremor
AT jogmandar realworldlongitudinalexperienceofbotulinumtoxintherapyforparkinsonandessentialtremor